Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-021481
Filing Date
2025-02-14
Accepted
2025-02-14 17:23:17
Documents
5

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 13801
2 EX-99.1 ck0001669811-ex99_1.htm EX-99.1 22959
3 EX-99.3 ck0001669811-ex99_3.htm EX-99.3 471671
4 EX-99.4 ck0001669811-ex99_4.htm EX-99.4 405278
5 EX-99.A ck0001669811-ex99_a.htm EX-99.A 64461
  Complete submission text file 0000950170-25-021481.txt   980564
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filed by) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Subject) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SCHEDULE 13D | Act: 34 | File No.: 005-48710 | Film No.: 25631076
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)